Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Overman

Showing results (181-190 of 265) with videos related to

Pageof 27
Sort By:
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Journal of Hematology & Oncology|July 3, 2026
KRAS inhibition is an effective therapy for appendiceal adenocarcinomaSaikat Chowdhury, Ichiaki Ito, Vinay K Pattalachinti, et al.
JAMA Network Open|May 17, 2023
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical TrialsMarcus A Florez, Joseph Abi Jaoude, Roshal R Patel, et al.
The Oncologist|April 14, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Margherita Ambrosini, Julien Taieb, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 6, 2025
Mutational and co-mutational landscape of early onset colorectal cancerJumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 7, 2017
Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicityRanda Tao, Chiaojung Jillian Tsai, Garrett Jensen, et al.
Cancer Research Communications|May 6, 2024
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal AdenocarcinomaNicholas J Hornstein, Mohammad A Zeineddine, Betul B Gunes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142T André, S Lonardi, K Y M Wong, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
Molecular Cancer Therapeutics|May 5, 2017
Modeling of Patient-Derived Xenografts in Colorectal CancerAnastasia Katsiampoura, Kanwal Raghav, Zhi-Qin Jiang, et al.
Pageof 27

Showing results (181-190 of 265) with videos related to

Sort By:
Pageof 27
Journal for Immunotherapy of Cancer|January 4, 2025
Early treatment discontinuation in patients with deficient mismatch repair or microsatellite instability high metastatic colorectal cancer receiving immune checkpoint inhibitorsJulien Taieb, Margherita Ambrosini, Emily Alouani, et al.
Journal of Hematology & Oncology|July 3, 2026
KRAS inhibition is an effective therapy for appendiceal adenocarcinomaSaikat Chowdhury, Ichiaki Ito, Vinay K Pattalachinti, et al.
JAMA Network Open|May 17, 2023
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical TrialsMarcus A Florez, Joseph Abi Jaoude, Roshal R Patel, et al.
The Oncologist|April 14, 2026
Mucinous histology and resistance to immune checkpoint blockade in patients with microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Margherita Ambrosini, Julien Taieb, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|January 6, 2025
Mutational and co-mutational landscape of early onset colorectal cancerJumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 7, 2017
Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicityRanda Tao, Chiaojung Jillian Tsai, Garrett Jensen, et al.
Cancer Research Communications|May 6, 2024
Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal AdenocarcinomaNicholas J Hornstein, Mohammad A Zeineddine, Betul B Gunes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 28, 2022
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142T André, S Lonardi, K Y M Wong, et al.
The Oncologist|August 20, 2025
First-line PD-1 +/- CTLA-4 blockade in patients with deficient mismatch repair and/or microsatellite instability-high metastatic colorectal cancerVincenzo Nasca, Gabriele Tinè, Julien Taieb, et al.
Molecular Cancer Therapeutics|May 5, 2017
Modeling of Patient-Derived Xenografts in Colorectal CancerAnastasia Katsiampoura, Kanwal Raghav, Zhi-Qin Jiang, et al.
Pageof 27